News Detail

China strengthens research and development of anticancer drugs, promotes the supply of patented drug

Issuing time:2018-08-14 00:00

In accordance with the National Medium- and Long-Term Science and Technology Development Plan, the “Major New Drug Creation” Science and Technology Major Project (hereinafter referred to as the “New Drug Special Project”) was launched in 2008. The new drug special project is a task-oriented scientific research project oriented to practical application and industrial development. By the end of 2017, more than 1,700 projects have been established, and a large number of varieties including special anti-cancer drugs have received new drug certificates, and 8 anti-tumor drugs have been approved. The medicine is awarded a new class 1 drug certificate. Among them, some varieties of special output have produced significant social and economic benefits.

The reporter learned from the National Health and Health Commission that in addition to the support for innovative drugs, the new drug specialization also supports the large-scale clinically needed varieties, transforming more than 200 kinds of clinically urgently needed varieties, involving more than 80 kinds of national essential drugs, and the quality of drugs has been greatly improved. Under the special support, China has gradually formed a grid innovation system based on the innovation of the source of research institutes and universities, the technological innovation based on enterprises, the close integration of the upper, middle and lower reaches, and the deep integration of government, industry, and research.

While encouraging drug innovation, the State Drug Administration has continued to accelerate the evaluation of the quality and efficacy of generic drugs and gradually improve the quality of listed drugs. For example, 36 work consistency assessment work documents were issued, work procedures and technical requirements were clarified, 16 batches of reference preparations were published, and 5 batches of catalogues that passed the consistency evaluation were published. 57 applications were approved for consistency and formulated for clinical publication. A list of drugs that can be substituted with the original drug, that is, the China Listed Drug List.

In terms of the supply of anticancer drugs, according to the “Guiding Opinions on Improving the Centralized Purchasing of Drugs in Public Hospitals”, relevant departments have launched pilot trials of national drug prices. In October 2015, the National Drug Price Negotiation Department Coordination Mechanism was established to launch the national drug price negotiation pilot. In May 2016, the results of the first batch of negotiations were announced. The purchase prices of tenofovir dipivoxil for hepatitis B and erfitinib and gefitinib for non-small cell lung cancer were reduced by 67% and 54%, respectively. 55%. In February 2017, these three countries negotiated drugs into the national basic medical insurance drug list. By the end of 2017, the government has reduced spending by more than 200 million yuan, and the accessibility and affordability of drugs have been significantly improved. The public's sense of gaining medical reform has actually increased. According to the institutional reform plan of the State Council, the National Drug Insurance Bureau is responsible for formulating and supervising the implementation of the drug bidding procurement policy.

At present, public hospitals implement classified procurement of drugs. For the basic drugs and non-patented drugs that are used in large quantities, high purchase amount, and produced by many enterprises, the provincial drug procurement agencies adopt the double-envelope system for public bidding and procurement, and the hospital as the purchasing entity, purchases the drugs according to the winning bid price; Exclusive production of medicines, establishment of an open and transparent, multi-participation price negotiation mechanism; non-patented medicines for women and children, urgent (robbing) medicines, basic infusions, and drugs with small clinical doses (the specific scope of the above drugs is determined by each province, city and city) ) and commonly used low-cost drugs to achieve centralized network, directly purchased by the hospital; for clinically necessary, small amount, market supply shortage of drugs, the state tenders for production, bargaining; for narcotic drugs, psychotropic drugs, prevention and treatment of infectious diseases and Free medication for parasitic diseases, national immunization program vaccines, family planning medicines and Chinese herbal medicines are purchased in accordance with current national regulations to ensure transparency.

The relevant person in charge of the National Health and Health Commission introduced that in the standardization of cancer diagnosis and treatment, the first is to improve relevant technical specifications, organize the development of various professional disease diagnosis and treatment guidelines and clinical technical operation specifications, and timely revision and revision of relevant disease diagnosis and treatment specifications. The second is to increase the intensity of diagnosis and treatment management, set up a national cancer standardization diagnosis and treatment quality control center for cancer diseases (located at the National Cancer Center), and established cancer quality control centers in 26 provinces to establish and improve the cancer quality control system. The third is to promote the application of new technologies for treatment, strengthen medical quality management, promulgate the implementation of the "Medical Quality Management Measures" in the form of departmental regulations, and constantly improve the medical quality management and clinical diagnosis and treatment related norms.

Recently, The Lancet released the latest global medical quality and accessibility rankings. China's HAQ (Medical Quality and Accessibility) ranking has increased from 60th in the world in 2015 to 48th in 2016, and significant progress has been made again. China's medical technology capabilities and medical quality improvement have been widely recognized internationally.

Share to:
Add:Room 3-21401, Wangting International, No. 80 Gaoxin Road, High-tech Zone, Xi'an
HOME            SUPPORT           PRODUCTS            ABOUT US           NEWS